Andrew Combs

PRLD

Andrew Combs serves as Chief Chemistry Officer at Prelude Therapeutics Incorporated (PRLD). This page tracks their complete SEC Form 4 insider trading history including stock purchases and sales.

Total Buys

3 trades

$249.7K

Total Sells

0 trades

$0.00

Net Position

Net Buyer

$249.7K

Companies Traded

PRLD

Active Period

Dec 2021 – Mar 2025

3 total trades

Most Recent

Buy PRLD

Mar 25, 2025 · $69.3K

Andrew Combs's Insider Trading at Prelude Therapeutics Incorporated (PRLD)

Buys

3 · $249.7K

Sells

0 · $0.00

Total Shares Bought

171,075

Total Shares Sold

PRLD Price Chart

Loading chart...

Date	Type	Shares	Avg Price	Value	Shares After
Mar 25, 2025	Buy	100,000	$0.69	$69.3K	0
Dec 26, 2024	Buy	63,075	$1.36	$85.5K	377,623
Dec 15, 2021	Buy	8,000	$11.86	$94.9K	268,380

Related Insiders

David P Bonita

director, 10 percent owner:

PRLDBuy · Apr 23, 2026

ORBIMED ADVISORS LLC

director, 10 percent owner:

PRLDBuy · Apr 23, 2026

BAKER BROS. ADVISORS LP

director, 10 percent owner:

PRLDBuy · Apr 22, 2026

Jane Huang

President, CMO

PRLDSell · Oct 4, 2025

Explore More Insider Trading Data

PRLD Insider Trading Activity

View all insider trades at Prelude Therapeutics Incorporated

Healthcare Sector Insider Trades

See insider activity across healthcare stocks

Latest Insider Buys

Most recent insider purchases across all stocks

CEO Stock Purchases

Track CEO buying activity